OpRegen Data Update to Be Featured in Presentation by Christopher D. Riemann, MD at 2020 American Academy of Ophthalmology Me...
October 15 2020 - 8:00AM
Business Wire
Lineage Also Will be Featured in Separate
Presentation Focused on Cell Based Therapies for AMD by Allen C.
Ho, MD
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
therapies for unmet medical needs, announced today that updated
interim results from a Phase 1/2a study of its lead product
candidate, OpRegen®, a retinal pigment epithelium cell transplant
therapy currently in development for the treatment of dry
age-related macular degeneration (AMD), will be presented at the
2020 American Academy of Ophthalmology Annual Meeting (AAO 2020),
to be held virtually (November 13-15, 2020). The presentation,
“Phase 1/2a Study of Subretinally Transplanted hESC-Derived RPE
Cells in Advanced Dry-Form AMD Patients” will be featured as part
of the Original Paper Session, OP02V Retina, Vitreous Original
Papers on November 15, 2020 between 7:40am to 8:25am Pacific Time
by Christopher D. Riemann, M.D., Vitreoretinal Surgeon and
Fellowship Director, Cincinnati Eye Institute (CEI) and University
of Cincinnati School of Medicine. (abstract number 30063541). In
addition, data from Lineage will be shown in a presentation by
Allen C. Ho, M.D. FACS, Wills Eye Hospital Attending Surgeon and
Director of Retina Research, Professor of Ophthalmology, Thomas
Jefferson University, entitled: “Cell Based Therapies and Surgical
Strategies for Atrophic Age-Related Macular Degeneration 2020,”
which is being presented as part of the AAO 2020 Retina
Subspecialty Day, on November 13, 2020 at 1:38pm Eastern Time.
The American Academy of Ophthalmology is the world’s largest
association of eye physicians and surgeons. A global community of
32,000 medical doctors, the AAO protects sight and empowers lives
by setting the standards for ophthalmic education and advocating
for our patients and the public. AAO innovates to advance our
profession and to ensure the delivery of the highest-quality eye
care. For more information, please visit www.aao.org or follow the
academy on Twitter @AAO.
About Dry AMD
Dry age-related macular degeneration (AMD) is a leading cause of
adult blindness in the developed world. There are two forms of AMD:
wet AMD and dry AMD. Dry AMD is the more common of the two types,
accounting for approximately 85-90% of cases. Wet AMD is the less
common of the two types, accounting for approximately 10-15% of
cases. Global sales of the two leading wet AMD therapies were in
excess of $10 billion in 2019. Nearly all cases of wet AMD begin as
dry AMD. Dry AMD typically affects both eyes. There are currently
no U.S. Food and Drug Administration (FDA) or European Medicines
Agency (EMA) approved treatment options available for patients with
dry AMD.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer. For
more information, please visit www.lineagecell.com or follow the
Company on Twitter @LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201015005190/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Russo Partners – Media Relations Nic Johnson or David
Schull Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com (212) 845-4242
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024